QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 evolent-health-explores-sale-garners-inbound-interest-from-private-equity-firms

Evolent Health is exploring a potential sale, drawing interest from private equity firms like TPG and KKR.

Core News & Articles

- Reuters Citing Sources

 cantor-fitzgerald-reiterates-overweight-on-elevance-health-maintains-600-price-target

Cantor Fitzgerald analyst Sarah James reiterates Elevance Health (NYSE:ELV) with a Overweight and maintains $600 price target.

 an-irrelevant-company-jim-cramer-says-snap-is-not-investable

Jim Cramer suggests buying Applied Materials despite government concerns, Aflac not favored, UnitedHealth Group best, Snap not ...

 cantor-fitzgerald-reiterates-overweight-on-elevance-health-maintains-600-price-target

Cantor Fitzgerald analyst Sarah James reiterates Elevance Health (NYSE:ELV) with a Overweight and maintains $600 price target.

 wells-fargo-maintains-overweight-on-elevance-health-lowers-price-target-to-593

Wells Fargo analyst Stephen Baxter maintains Elevance Health (NYSE:ELV) with a Overweight and lowers the price target from $...

 td-cowen-maintains-buy-on-elevance-health-lowers-price-target-to-589

TD Cowen analyst Ryan Langston maintains Elevance Health (NYSE:ELV) with a Buy and lowers the price target from $624 to $589.

 bofa-downgrades-elevance-health-on-medicaid-pressure-and-lowered-peer-valuations

Elevance Health reports Q2 revenues of $43.2 billion, slightly above consensus despite a 0.4% YoY decline driven by Medicaid me...

 barclays-maintains-overweight-on-elevance-health-lowers-price-target-to-611

Barclays analyst Andrew Mok maintains Elevance Health (NYSE:ELV) with a Overweight and lowers the price target from $621 to ...

 rbc-capital-maintains-outperform-on-elevance-health-raises-price-target-to-585

RBC Capital analyst Ben Hendrix maintains Elevance Health (NYSE:ELV) with a Outperform and raises the price target from $575...

 b-of-a-securities-downgrades-elevance-health-to-neutral-lowers-price-target-to-530

B of A Securities analyst Kevin Fischbeck downgrades Elevance Health (NYSE:ELV) from Buy to Neutral and lowers the price tar...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION